Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination.

Autor: Matsui Y; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA., Li L; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Prahl M; Department of Pediatrics.; Division of Pediatric Infectious Diseases and Global Health., Cassidy AG; Division of Maternal-Fetal Medicine and., Ozarslan N; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Golan Y; Department of Bioengineering and Therapeutic Sciences., Gonzalez VJ; Division of Maternal-Fetal Medicine and., Lin CY; Division of Maternal-Fetal Medicine and., Jigmeddagva U; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Chidboy MA; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Montano M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA., Taha TY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Khalid MM; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Sreekumar B; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Hayashi JM; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Chen PY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Kumar GR; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA., Warrier L; Department of Family Health Care Nursing, and., Wu AH; Department of Laboratory Medicine, UCSF, San Francisco, California, USA., Song D; Department of Pediatrics, Division of Neonatology, Santa Clara Valley Medical Center, San Jose, California, USA., Jegatheesan P; Department of Pediatrics, Division of Neonatology, Santa Clara Valley Medical Center, San Jose, California, USA., Rai DS; Stanford-O'Connor Family Medicine Residency Program, Division of Family Medicine, Stanford University, Palo Alto, California, USA., Govindaswami B; Department of Pediatrics, Division of Neonatology, and., Needens J; Department of Obstetrics and Gynecology, Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia, USA., Rincon M; Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon, USA., Myatt L; Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon, USA., Asiodu IV; Department of Family Health Care Nursing, and., Flaherman VJ; Department of Pediatrics., Afshar Y; Department of Obstetrics and Gynecology, UCLA, Los Angeles, California, USA., Jacoby VL; Department of Obstetrics, Gynecology & Reproductive Sciences., Murtha AP; Division of Maternal-Fetal Medicine and., Robinson JF; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA., Ott M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA.; Department of Medicine, and., Greene WC; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, California, USA.; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, California, USA.; Department of Medicine, and.; Department of Microbiology and Immunology, UCSF, San Francisco, California, USA., Gaw SL; Division of Maternal-Fetal Medicine and.; Center for Reproductive Sciences, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: JCI insight [JCI Insight] 2022 Jun 22; Vol. 7 (12). Date of Electronic Publication: 2022 Jun 22.
DOI: 10.1172/jci.insight.157354
Abstrakt: Pregnancy confers unique immune responses to infection and vaccination across gestation. To date, there are limited data comparing vaccine- and infection-induced neutralizing Abs (nAbs) against COVID-19 variants in mothers during pregnancy. We analyzed paired maternal and cord plasma samples from 60 pregnant individuals. Thirty women vaccinated with mRNA vaccines (from December 2020 through August 2021) were matched with 30 naturally infected women (from March 2020 through January 2021) by gestational age of exposure. Neutralization activity against the 5 SARS-CoV-2 spike sequences was measured by a SARS-CoV-2-pseudotyped spike virion assay. Effective nAbs against SARS-CoV-2 were present in maternal and cord plasma after both infection and vaccination. Compared with WT spike protein, these nAbs were less effective against the Delta and Mu spike variants. Vaccination during the third trimester induced higher cord-nAb levels at delivery than did infection during the third trimester. In contrast, vaccine-induced nAb levels were lower at the time of delivery compared with infection during the first trimester. The transfer ratio (cord nAb level divided by maternal nAb level) was greatest in mothers vaccinated in the second trimester. SARS-CoV-2 vaccination or infection in pregnancy elicits effective nAbs with differing neutralization kinetics that are influenced by gestational time of exposure.
Databáze: MEDLINE